Initial module submission marks an important milestone in the pre-market approval process - - Flexible modular submission ...

In a report released yesterday, Yigal Nochomovitz from Citi maintained a Buy rating on Alpha Tau Medical Ltd (DRTS – Research Report), with a price target of $8.00. Yigal Nochomovitz has given his Buy ...

Alpha Tau Medical Ltd. announced significant advancements in their alpha-radiation cancer treatment, Alpha DaRT®, during the 2025 ASCO GI Symposium and R&D Update Day. Interim results from three ...

Alpha Tau reports promising Alpha DaRT trial results in pancreatic cancer and head and neck cancer, with significant survival benefits. High disease control rate (91% DCR) and positive interim safety ...